Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
Fulgent Genetics has a diagnostics base and a cancer drug signal. FID-007 now faces the tougher Phase 3 test.
Pharma & Biotech
Pharma & Biotech
Can China Medical University Hospital, Ever Supreme and SHINE OUT BIO reshape spinal cord injury repair?
New exosome therapy targets spinal cord injury repair non-invasively. Find out how this breakthrough could reshape neuroregenerative medicine.
Medical Devices & Diagnostics
What the nanoparticle BCI model reveals about the future of brain interfaces
Subsense, Inc. has raised an additional $10 million in funding to accelerate the development of its non-surgical, nanoparticle-based brain-computer interface (BCI), bringing its total funding to $27 million. The financing, led by Golden Falcon Capital, follows early successes in nanoparticle design, in vitro signal stimulation, and the construction of a bio-integrated hardware-software platform intended to